Phillip Gutry
Plus aucun poste en cours
Profil
Phillip P.
Gutry worked as a Director of Corporate Development at Gilead Sciences, Inc. from 2006 to 2011.
He then worked as a Principal at MPM BioImpact, Inc. from 2011 to 2015.
From 2015 to 2018, he was an Executive Director of Business Development at Regeneron Pharmaceuticals, Inc. He also served as a Director at Potenza Therapeutics, Inc. and Amphivena Therapeutics, Inc. Additionally, he was an Independent Director at Avalo Therapeutics, Inc. from 2015 to 2021.
From 2018 to 2020, he was the Chief Business Officer at Kronos Bio, Inc. and later served as the CFO, Chief Business & Accounting Officer at Graphite Bio, Inc. Mr. Gutry received his undergraduate degree from Dartmouth College and his MBA from The Wharton School of the University of Pennsylvania.
Anciens postes connus de Phillip Gutry
| Sociétés | Poste | Fin |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director/Board Member | 01/11/2021 |
| KRONOS BIO, INC. | Corporate Officer/Principal | 01/10/2020 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/10/2018 |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/06/2015 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/05/2011 |
Formation de Phillip Gutry
| Dartmouth College | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| KRONOS BIO, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Potenza Therapeutics, Inc.
 Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Wilkerson Group
 Wilkerson Group Medical/Nursing ServicesHealth Services Part of International Business Machines Corp., Wilkerson Group is a consulting private company that provides services to the pharmaceutical and medical products industry. The company is based in New York, NY. The company was founded by Kenneth D. Noonan. The CEO is Neil MacAllister. Wilkerson Group was acquired by International Business Machines Corp. on April 01, 1996. | Health Services |
Riverside Partners LLC
 Riverside Partners LLC Investment ManagersFinance Riverside Partners LLC (Riverside Partners) is a private equity firm founded in 1989. The firm is headquartered in Boston, Massachusetts. | Finance |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
